Synerkine Pharma Raises EUR3.3 Million in Series A Financing

25 March 2019, Utrecht, The Netherlands – Synerkine Pharma B.V., which develops fusion proteins for the treatment of chronic pain, announced today that it successfully closed a EUR 3.3 million Series A financing from Thuja Capital, an undisclosed private investor, and the company’s founders.

Hans Preusting, co-founder and CEO of Synerkine Pharma, said: “We are delighted with the closing of the Series A financing. The proceeds will allow us to deliver a pre-clinical proof of concept in osteoarthritis and neuropathic pain over the next two years. Our lead compound licensed from the University Medical Center Utrecht (UMCU), a fusion protein of IL4 and IL10, has been shown to significantly reduce chronic pain in multiple pre-clinical models. The therapeutic potential of fusion proteins that mimic endogenous immune molecules and are devoid of the typical analgesic side-effects is substantial in a broad range of pain indications.”

About Synerkine Pharma

Synerkine Pharma focuses on developing novel fusion proteins for the treatment of inflammatory, neuropathic and osteoarthritic pain. Synerkine Pharma was founded in 2018 and has licensed the exclusive rights of its lead compound, a fusion protein of IL4 and IL10, from the University Medical Center Utrecht (UMCU), the Netherlands. This fusion protein targets common regulatory mechanisms in different types of chronic pain, and has unique properties as demonstrated by UMCU researchers, who showed that it is effective in reducing pain in multiple pre-clinical models. The ability to treat pain with drugs that mimic endogenous immune molecules and are based on a different mechanism of action than the current anti-analgesic drugs holds tremendous therapeutic and commercial potential.

For further enquiries:

Hans Preusting, PhD, MBA
Chief Executive Officer
+31 620 783 355
hans@synerkinepharma.com



ATRO Medical obtains permission to start clinical study with knee meniscus prosthesis

ATRO Medical obtains permission to start clinical study with knee meniscus prosthesis

10 December 2018, Nijmegen, The Netherlands – ATRO Medical BV has obtained permission from the Healthcare and Youth Inspection to implant the meniscal prosthesis Trammpolin® in eighteen patients. ATRO Medical BV does this together with Radboudumc, the Maastricht UMC+ and the Sint Maartenskliniek. This clinical study is used to determine whether Trammpolin® leads to less pain and a more resilient knee in patients.

Cristal Therapeutics appoints Dr. Axel Mescheder as CEO and CMO

Cristal Therapeutics appoints Dr. Axel Mescheder as CEO and CMO

2 November 2018, Maastricht, The Netherlands – Cristal Therapeutics has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO).

Cristal Therapeutics initiates phase 2 clinical trial with CriPec docetaxel in ovarian cancer

Cristal Therapeutics initiates phase 2 clinical trial with CriPec docetaxel in ovarian cancer

25 October 2018 , Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for the treatment of cancer and other diseases, announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer.

MILabs’ VECTor6 with groundbreaking PET performance awarded Innovation of the Year at the WMIC 2018

MILabs’ VECTor6 with groundbreaking PET performance awarded Innovation of the Year at the WMIC 2018

15 September 2018, Utrecht, The Netherlands – MILabs is pleased to announce that its new VECTor6 with Broadband Photon Tomography technique has received the Commercial Innovation Award at the World Molecular Imaging Congress (WMIC) in Seattle September 12th-15th, 2018.

Thuja invests in Salvia BioElectronics

Thuja invests in Salvia BioElectronics

22 May 2018, Eindhoven – Salvia BioElectronics B.V. announced today that it secured € 1.3 million in seed funding to develop a minimally invasive bioelectronics solution for people suffering from chronic neurological disease. The funding is provided by a syndicate led by Thuja Capital Healthcare Seed Fund II and the Brabant Development Agency (BOM), and includes the Netherlands Enterprise Agency (RVO.nl) and founders and employees of Salvia.

Thuja Capital exits NightBalance to Philips

 Thuja Capital exits NightBalance to Philips

8 May, 2018, Utrecht, The Netherlands – Thuja Capital announced it has sold its shareholding in NightBalance B.V. (The Hague, Netherlands) to Royal Philips (NYSE: PHG, AEX: PHIA).

Philips has agreed to acquire all outstanding shares of NightBalance, a digital health scale-up company that has developed an innovative, easy to use device to treat positional obstructive sleep apnea and positional snoring.

NutriLeads wins EUR 2.5M Horizon2020 SME funding

NutriLeads wins EUR 2.5M Horizon2020 SME funding

March 29, Wageningen, The Netherlands. NutriLeads, a Dutch Health Ingredients company announces that its NUTRI-NEED project has been selected for €2.5 million funding under the European Innovation Council SME Instrument (phase 2). The aim of the 2-year project is to prepare NutriLeads’ health promoting food ingredient NL-01 for commercialization.

NightBalance obtains reimbursement in the Netherlands for its innovative sleep apnea therapy

NightBalance obtains reimbursement in the Netherlands for its innovative sleep apnea therapy

22 December 2017, The Hague, The Netherlands – NightBalance, a leader in innovative obstructive sleep apnea (OSA) therapies, today announced that the Dutch National Health Care Institute (ZIN) issued a positive recommendation to include its sleep apnea therapy for reimbursement. The Dutch Ministry of Health, Welfare and Sport will formally approve inclusion of the SPT® following ZIN’s recommendation.

Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials

Cristal Therapeutics awarded €2.5 million Horizon 2020 grant to advance its CriPec®-docetaxel through Phase 2 trials

28 November 2017, Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage biopharmaceutical company developing targeted nanomedicines for the treatment of cancer and other diseases with high unmet patient need, today announced that it secured a €2.5 million grant from the European Commission’s Horizon 2020 programme. 

MILabs’ VECTor6 with groundbreaking PET performance awarded Innovation of the Year at the WMIC 2018

MILabs’ VECTor6 with groundbreaking PET performance awarded Innovation of the Year at the WMIC 2018

15 September 2018, Utrecht, The Netherlands – MILabs is pleased to announce that its new VECTor6 with Broadband Photon Tomography technique has received the Commercial Innovation Award at the World Molecular Imaging Congress (WMIC) in Seattle September 12th-15th, 2018.

Cristal Therapeutics initiates phase 2 clinical trial with CriPec docetaxel in ovarian cancer

Cristal Therapeutics initiates phase 2 clinical trial with CriPec docetaxel in ovarian cancer

25 October 2018 , Maastricht, The Netherlands – Cristal Therapeutics, a clinical stage pharmaceutical company developing unique nanomedicines for the treatment of cancer and other diseases, announced today the first patient has been dosed in its Phase 2 clinical trial of lead nanomedicine candidate CPC634 for patients with platinum-resistant ovarian cancer.

Cristal Therapeutics appoints Dr. Axel Mescheder as CEO and CMO

Cristal Therapeutics appoints Dr. Axel Mescheder as CEO and CMO

2 November 2018, Maastricht, The Netherlands – Cristal Therapeutics has appointed Dr. Axel Mescheder to the role of Chief Executive Officer (CEO) with immediate effect. He will also serve as Chief Medical Officer (CMO).